Publication

Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study

Ananias, H. J. K., Yu, Z., Hoving, H. D., Rosati, S., Dierckx, R. A., Wang, F., Yan, Y., Chen, X., Pruim, J., Lub-de Hooge, M. N., Helfrich, W., Elsinga, P. H. & de Jong, I. J., Oct-2013, In : Nuclear Medicine and Biology. 40, 7, p. 933-938 6 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Ananias, H. J. K., Yu, Z., Hoving, H. D., Rosati, S., Dierckx, R. A., Wang, F., ... de Jong, I. J. (2013). Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study. Nuclear Medicine and Biology, 40(7), 933-938. https://doi.org/10.1016/j.nucmedbio.2013.05.009

Author

Ananias, Hildo J. K. ; Yu, Zilin ; Hoving, Hilde D. ; Rosati, Stefano ; Dierckx, Ruth A. ; Wang, Fan ; Yan, Yongjun ; Chen, Xiaoyuan ; Pruim, Jan ; Lub-de Hooge, Marjolijn N. ; Helfrich, Wijnand ; Elsinga, Philip H. ; de Jong, Igle J. / Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study. In: Nuclear Medicine and Biology. 2013 ; Vol. 40, No. 7. pp. 933-938.

Harvard

Ananias, HJK, Yu, Z, Hoving, HD, Rosati, S, Dierckx, RA, Wang, F, Yan, Y, Chen, X, Pruim, J, Lub-de Hooge, MN, Helfrich, W, Elsinga, PH & de Jong, IJ 2013, 'Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study', Nuclear Medicine and Biology, vol. 40, no. 7, pp. 933-938. https://doi.org/10.1016/j.nucmedbio.2013.05.009

Standard

Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study. / Ananias, Hildo J. K.; Yu, Zilin; Hoving, Hilde D.; Rosati, Stefano; Dierckx, Ruth A.; Wang, Fan; Yan, Yongjun; Chen, Xiaoyuan; Pruim, Jan; Lub-de Hooge, Marjolijn N.; Helfrich, Wijnand; Elsinga, Philip H.; de Jong, Igle J.

In: Nuclear Medicine and Biology, Vol. 40, No. 7, 10.2013, p. 933-938.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Ananias HJK, Yu Z, Hoving HD, Rosati S, Dierckx RA, Wang F et al. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study. Nuclear Medicine and Biology. 2013 Oct;40(7):933-938. https://doi.org/10.1016/j.nucmedbio.2013.05.009


BibTeX

@article{9bcd871b30c44ab598a4b113518f8ab2,
title = "Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study",
abstract = "Rationale: The peptide bombesin (BBN) and its derivatives exhibit high binding affinity for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in prostate cancer. We used the BBN-based radiopharmaceutical (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) (Tc-99m-HABBN) to perform a first-in-man clinical pilot study to evaluate the feasibility of Tc-99m-HABBN SPECT/CT for detection of prostate cancer in patients.Methods: Eight patients with biopsy-proven prostate cancer who were scheduled for either radical prostatectomy or external beam radiotherapy underwent Tc-99m-HABBN scintigraphy and SPECT/CT prior to treatment. Serial blood samples were taken to assess blood radioactivity and to determine in vivo metabolic stability. Clinical parameters were measured and reported side effects, if present, were recorded. Prostate cancer specimens of all patients were immunohistochemically stained for GRPR.Results: Tc-99m-HABBN was synthesized with high radiochemical yield, purity and specific activity. There were no significant changes in clinical parameters, and there were no adverse or subjective side effects. Low metabolic stability was observed, as less than 20{\%} of Tc-99m-HABBN was intact after 30 min. Immunohistochemical staining for GRPR was observed in the prostate cancer specimens in all patients. Tc-99m-HABBN scintigraphy and SPECT/CT did not detect prostate cancer in patients with proven disease.Conclusions: Tc-99m-HABBN SPECT/CT for visualization of prostate cancer is safe but hampered by an unexpected low in vivo metabolic stability in man. The difference between the excellent in vitro stability of Tc-99m-HABBN in human serum samples determined in our previous study regarding Tc-99m-HABBN and the low in vivo metabolic stability determined in this study, is striking. This issue warrants further study of peptide-based radiopharmaceuticals. (C) 2013 Elsevier Inc. All rights reserved.",
keywords = "Prostate cancer, SPECT/CT, Bombesin, GRPR, First-in-man, GASTRIN-RELEASING-PEPTIDE, RADIOLABELED BOMBESIN ANALOGS, RECEPTOR, IMMUNOREACTIVITY, BIOPSIES",
author = "Ananias, {Hildo J. K.} and Zilin Yu and Hoving, {Hilde D.} and Stefano Rosati and Dierckx, {Ruth A.} and Fan Wang and Yongjun Yan and Xiaoyuan Chen and Jan Pruim and {Lub-de Hooge}, {Marjolijn N.} and Wijnand Helfrich and Elsinga, {Philip H.} and {de Jong}, {Igle J.}",
year = "2013",
month = "10",
doi = "10.1016/j.nucmedbio.2013.05.009",
language = "English",
volume = "40",
pages = "933--938",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "ELSEVIER SCIENCE INC",
number = "7",

}

RIS

TY - JOUR

T1 - Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients A first-in-man study

AU - Ananias, Hildo J. K.

AU - Yu, Zilin

AU - Hoving, Hilde D.

AU - Rosati, Stefano

AU - Dierckx, Ruth A.

AU - Wang, Fan

AU - Yan, Yongjun

AU - Chen, Xiaoyuan

AU - Pruim, Jan

AU - Lub-de Hooge, Marjolijn N.

AU - Helfrich, Wijnand

AU - Elsinga, Philip H.

AU - de Jong, Igle J.

PY - 2013/10

Y1 - 2013/10

N2 - Rationale: The peptide bombesin (BBN) and its derivatives exhibit high binding affinity for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in prostate cancer. We used the BBN-based radiopharmaceutical (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) (Tc-99m-HABBN) to perform a first-in-man clinical pilot study to evaluate the feasibility of Tc-99m-HABBN SPECT/CT for detection of prostate cancer in patients.Methods: Eight patients with biopsy-proven prostate cancer who were scheduled for either radical prostatectomy or external beam radiotherapy underwent Tc-99m-HABBN scintigraphy and SPECT/CT prior to treatment. Serial blood samples were taken to assess blood radioactivity and to determine in vivo metabolic stability. Clinical parameters were measured and reported side effects, if present, were recorded. Prostate cancer specimens of all patients were immunohistochemically stained for GRPR.Results: Tc-99m-HABBN was synthesized with high radiochemical yield, purity and specific activity. There were no significant changes in clinical parameters, and there were no adverse or subjective side effects. Low metabolic stability was observed, as less than 20% of Tc-99m-HABBN was intact after 30 min. Immunohistochemical staining for GRPR was observed in the prostate cancer specimens in all patients. Tc-99m-HABBN scintigraphy and SPECT/CT did not detect prostate cancer in patients with proven disease.Conclusions: Tc-99m-HABBN SPECT/CT for visualization of prostate cancer is safe but hampered by an unexpected low in vivo metabolic stability in man. The difference between the excellent in vitro stability of Tc-99m-HABBN in human serum samples determined in our previous study regarding Tc-99m-HABBN and the low in vivo metabolic stability determined in this study, is striking. This issue warrants further study of peptide-based radiopharmaceuticals. (C) 2013 Elsevier Inc. All rights reserved.

AB - Rationale: The peptide bombesin (BBN) and its derivatives exhibit high binding affinity for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in prostate cancer. We used the BBN-based radiopharmaceutical (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) (Tc-99m-HABBN) to perform a first-in-man clinical pilot study to evaluate the feasibility of Tc-99m-HABBN SPECT/CT for detection of prostate cancer in patients.Methods: Eight patients with biopsy-proven prostate cancer who were scheduled for either radical prostatectomy or external beam radiotherapy underwent Tc-99m-HABBN scintigraphy and SPECT/CT prior to treatment. Serial blood samples were taken to assess blood radioactivity and to determine in vivo metabolic stability. Clinical parameters were measured and reported side effects, if present, were recorded. Prostate cancer specimens of all patients were immunohistochemically stained for GRPR.Results: Tc-99m-HABBN was synthesized with high radiochemical yield, purity and specific activity. There were no significant changes in clinical parameters, and there were no adverse or subjective side effects. Low metabolic stability was observed, as less than 20% of Tc-99m-HABBN was intact after 30 min. Immunohistochemical staining for GRPR was observed in the prostate cancer specimens in all patients. Tc-99m-HABBN scintigraphy and SPECT/CT did not detect prostate cancer in patients with proven disease.Conclusions: Tc-99m-HABBN SPECT/CT for visualization of prostate cancer is safe but hampered by an unexpected low in vivo metabolic stability in man. The difference between the excellent in vitro stability of Tc-99m-HABBN in human serum samples determined in our previous study regarding Tc-99m-HABBN and the low in vivo metabolic stability determined in this study, is striking. This issue warrants further study of peptide-based radiopharmaceuticals. (C) 2013 Elsevier Inc. All rights reserved.

KW - Prostate cancer

KW - SPECT/CT

KW - Bombesin

KW - GRPR

KW - First-in-man

KW - GASTRIN-RELEASING-PEPTIDE

KW - RADIOLABELED BOMBESIN ANALOGS

KW - RECEPTOR

KW - IMMUNOREACTIVITY

KW - BIOPSIES

U2 - 10.1016/j.nucmedbio.2013.05.009

DO - 10.1016/j.nucmedbio.2013.05.009

M3 - Article

VL - 40

SP - 933

EP - 938

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 7

ER -

ID: 5959605